Polycystic Ovary Syndrome Pathophysiology: Integrating Systemic, CNS and Circadian Processes.
George Anderson
https://pubmed.ncbi.nlm.nih.gov/38287831/Actively Recruiting
Led by Mila Mend Inc. · Updated on 2026-08-13
225
Participants Needed
1
Research Sites
9 weeks
Total Duration
Researchers are evaluating the effects of a consumer-grade product called Milamend Hormone Balance on quality of life and hormonal health in women who report symptoms associated with Polycystic Ovarian Syndrome PCOS. The study aims to observe changes in menstrual cycle structure, reproductive and metabolic markers, body image concerns, anxiety, and general well-being in premenopausal women. This observational study uses self-reported measures, cycle tracking, and at-home blood sample collection without establishing a doctor-patient relationship. The study compares women using the Milamend Hormone Balance supplement with those using a placebo. Participants take 1 scoop mixed with at least 8 ounces of water daily for the first 3 days, then increase to 1 scoop twice daily with food. The product contains ingredients intended to support hormonal balance, insulin sensitivity, mitochondrial function, and overall health. The study includes a placebo arm and an experimental arm using the supplement. Participants provide data through questionnaires and surveys, track menstrual cycles, and collect blood samples at home over up to 16 weeks. Researchers assess quality of life, menstrual cycle frequency and symptoms, general well-being, anxiety, body image, hormone and metabolic blood markers, and safety throughout 12 to 13 weeks. The study monitors tolerability and formulation effects, contributing to future research design.
CONDITIONS
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.
N
Noah Craft, M.D., Ph.D
C
Crisel Erfe, M.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mila Mend Inc.
Lead Sponsor
People Science, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Milamend dietary supplement (investigational) | Placebo powder (trial comparator) | Combined oral contraceptive (standard therapy) |
|---|---|---|---|
| What it is | A dietary supplement powder containing inositols, vitamins, minerals, amino acids, and other ingredients designed to support hormone balance in women with self‑reported PCOS symptoms | A matched placebo powder with same dosing schedule used as the control comparator in the trial | Combined oral contraceptive pills are commonly used to manage menstrual irregularity and signs of hyperandrogenism in women with PCOS |
| Role in the trial | Experimental intervention under investigation | Control comparator using identical administration without active ingredients | Typical first‑line treatment used outside the trial but not tested here |
| Primary use | Being evaluated for hormone balance, menstrual cycle regularity, quality of life, metabolic and hormonal outcomes | Used to measure background effect versus no active supplement | Used in routine care to regulate menstrual cycles and reduce androgen‑related symptoms |
| How it is given or performed | Powder taken as 1 scoop per day with water for 3 days, then increased to one scoop twice daily with food | Identical dosing schedule as the supplement arm without active ingredients | Oral daily pill containing both estrogen and progestin |
| Evidence status | Efficacy is being evaluated in this ongoing randomized placebo‑controlled trial; results not yet available | No active effect expected; serves as control | Management of menstrual irregularity and hyperandrogenism supported by strong guideline recommendations |
| Important limitations | Study results are pending; supplement’s efficacy and safety remain unknown | Placebo provides no active treatment and does not offer clinical benefit | Not studied in this trial; may involve hormonal side effects and is not directly comparable to a non‑hormonal supplement |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (remote or in-person)
Duration - Up to 16 weeks
Participants take either the Milamend Hormone Balance supplement or placebo powder daily, starting with once daily for 3 days then twice daily with food. They track symptoms, complete questionnaires, and collect blood samples at home.
Monthly remote assessments and blood collections
Duration - Up to 1 month after treatment
Researchers review collected data on quality of life, menstrual cycles, hormonal and metabolic markers, anxiety, body image, and safety.
1 final remote assessment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
George Anderson
https://pubmed.ncbi.nlm.nih.gov/38287831/Panagiota Florou, Panagiotis Anagnostis, Patroklos Theocharis...
https://pubmed.ncbi.nlm.nih.gov/32767206/Elif Günalan, Aylin Yaba, Bayram Yılmaz
https://pubmed.ncbi.nlm.nih.gov/30299265/David Finlay, Doreen Cantrell
https://pubmed.ncbi.nlm.nih.gov/21421912/Xiangbing Mao, Xiangfang Zeng, Shiyan Qiao...
https://pubmed.ncbi.nlm.nih.gov/21622125/M Nordio, S Basciani, E Camajani
https://pubmed.ncbi.nlm.nih.gov/31298405/Min-Hyun Kim, Hyeyoung Kim
https://pubmed.ncbi.nlm.nih.gov/28498331/Sumithra N C Unni, Lakshmi R Lakshman, Kannan Vaidyanathan...
https://pubmed.ncbi.nlm.nih.gov/26658589/Lorena Carboni
https://pubmed.ncbi.nlm.nih.gov/35999905/Marzenna Nasiadek, Joanna Stragierowicz, Michał Klimczak...
https://pubmed.ncbi.nlm.nih.gov/32824334/Mila Mend Inc.
Lead Sponsor
People Science, Inc.
Collaborating Sponsor